miDiagnostics is revolutionizing healthcare with its proprietary, innovative RT-PCR technology, based on a nanofluidic processor on a chip. This technology enables rapid and accurate diagnostic tests, making it applicable for various therapeutic needs. miDiagnostics ensures the highest quality in its solutions, supporting biopharmaceutical companies and clinicians in delivering safe, advanced therapeutic solutions.
Molecular Diagnostic
miDiagnostics is developing a molecular diagnostics pipeline, using its ultra-fast PCR technology, for a wide range of therapeutic needs. From sterility testing, towards respiratory indications, and many other others.
The miDiagnostics’ COVID-19 PCR Test* with its optimized workflow, compact design, and ultra-fast and reliable results make it optimally suited for use in a decentralized testing approach.
*discontinued since May 2025.
Ultra-fast.
Ultra-reliable.
Our COVID-19 PCR test* combines the convenience and speed of an antigen test with the sensitivity of a Polymerase Chain Reaction (PCR) test.
*discontinued since May 2025
“miDiagnostics has the potential to disrupt and transform the industry by making diagnostic information available to clinician and patient alike.”
“Its easy-to-use and cost-efficient test will revolutionize point-of-care testing by directly engaging with patients and enabling speedy intervention.”
“Proud to be leading a top team and together with our numerous partners to make a significant contribution to healthcare in general.”
“As a Non-Executive Director on miDiagnostics’ Board, I have been privileged to witness its continued development. I am very proud to see many years of hard work coming to fruition and providing value, facilitating the return to a normal way of life, with potential to move high quality testing closer to the patient.”
“This technology could aid the management of outbreaks in challenging settings, such as nursing homes and home care environments, allowing healthcare professionals to adjust their management decisions at the point of care. ”
